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Background. Elderly women with breast cancer are considered underdiagnosed and undertreated, and this adversely aﬀects their
overall survival. Methods. A total of 393 female breast cancer patients aged 70 years and older, diagnosed within the years 1989–
1999, were identiﬁed from the tumor registry of The Brooklyn Hospital Center. Comparisons between the 3 diﬀerent subgroups
70–74, 75–79, and 80 years and older were made using the Pearson Chi Square test. Results. Lumpectomy was performed in 42%
of all patients, while mastectomy was done in 46% of patients. Adjuvant therapy such as chemotherapy, radiation therapy, and
hormonal therapy were done in 12%, 25%, and 38%, respectively. Forty-seven percent of patients with positive lymph nodes
received chemotherapy. Eighty-six percent of patients who were estrogen receptor-positive received adjuvant hormonal therapy.
Overall ﬁve-year survival was only 14% for the ≥80 age group, compared to that of 32% and 35% for the 70–74 and the 75–79
age groups, respectively. Conclusions. Surgery was performed in majority of these patients, about half received lumpectomy, the
other half mastectomy. Adjuvant therapies were frequently excluded, with only hormonal therapy being the most commonly used.
Overall ﬁve-year survival is signiﬁcantly worse in patients ≥80 years with breast cancer.
1.Introduction
Breast cancer is still the most common cause of death for
women in the United States. Interestingly, we see that as the
population ages, we likewise see an increase in the number
of patients diagnosed with breast cancer. Increasing age
remains the greatest risk factor in developing the disease. It
is estimated that by 2030, 20% of Americans will be over the
age of 65. Studies have shown that around 50% of patients
with breast cancer are those older than 65 years of age and
that approximately 35% are older than 70 years [1, 2]. Most
women who die of breast cancer are over the age of 65
[3,4].Yetdespitethisinformation,itisobservedinanumber
of studies that elderly patients do not receive the standard
treatment when compared to their younger counterparts
[5, 6]. And at the heart of this dilemma is that as patients
advance in age, the incidence of cancer increases, but so does
signiﬁcant medical comorbidities. And it is the latter that
may signiﬁcantly aﬀect treatment options in most patients.
However, a number of studies have cited that age alone was
a determining factor in the type of treatment a patient with
breast cancer would receive [7, 8].
Studies collectively show that older patients with breast
cancer are more likely to be undertreated compared to
younger patients [9, 10]. To date, there is no consensus as
to what the best treatment is for older patients [9]. Part of
it is because older breast cancer patients are not very well
represented in clinical trials [11]. There are also suggestions
that treatment should include consideration of nonbreast-
cancer-speciﬁc survival, functional status, and patient and
family preference (goals of care). In terms of life expectancy,
data from the National Vital Statistics Reports from the
Centers for Disease Control and Prevention (CDC) released
in 2003 have shown that females at age 70 have an average
life expectancy of 15 years if they are relatively healthy and 7
years for those over 85 years old [12]. The care for an elderly
breast cancer patient is indeed very complicated. Thus,
treatment of an elderly patient should be multidisciplinary,
possibly requiring the expertise of a primary care physician,
a geriatrician, a psychiatrist, a surgeon, and a medical and
radiation oncologist.
Screening is likewise very controversial in the elderly
population. There are very few retrospective and prospective2 International Journal of Breast Cancer
studies looking speciﬁcally at cancer screening in the elderly.
T h eU SP r e v e n t i v eS e r v i c e sT a s kF o r c e( U S P S T F )r e c o m -
mends screening mammography, with or without clinical
breast examination (CBE), every 1-2 years for women aged
40 and older [13]. Despite this, however, mammography was
noted to be used 72% as adjunct to clinical examination
in these older women and only around 30%–38% in
women over 80 with occult disease [14]. These suggest that
mammography was not largely used for screening purposes
in the elderly patient with breast cancer [14].
Knowing that around 77% of deaths attributed to breast
cancer are in women older than 55 years of age, it is truly
interesting to note that there is an observed age-related
diﬀerence in treatment and screening for breast cancer.
The study intend to determine whether treatment of and
screening for breast cancer in the elderly in a community
hospital is appropriate. Improved treatment of older patients
with breast cancer is of paramount importance if we are to
properlyaddressthegrowingnumberofcasesanddeathsdue
to breast cancer.
2. Methods
The investigators identiﬁed the patients in the study using
the American College of Surgeons Committee on Cancer-
accredited tumor registry database of The Brooklyn Hospital
Center. Patients between the years 1989–1999 were included
in the study if they were older than 70 years old at the
time of breast cancer diagnosis. The patients were then
subsequently divided into three age subgroups: 70–74, 75–
79, and ≥80, roughly corresponding to the age categories
usedinthegeriatricpopulation—theyoungold(often65–74
years), the middle old (75–85 years), and the very oldest old
(≥95 years). The following information for each subgroup
were gathered from the registry: size, grade, histologic type
of tumor, complete staging, estrogen receptor status, type
of surgical procedure done, type of adjuvant therapy given,
and survival data 5 years after diagnosis. The Pearson Chi-
square test was used to compare patient characteristics and
types of treatment between patient groups. A P value of
0.05 was designated as being signiﬁcant. The protocol was
approved by The Brooklyn Hospital Center’s Institutional
Review Board (IRB).
3. Results
There were a total of 393 female patients (age over 70 years)
treated for breast cancer at the Brooklyn Hospital center
between January 1989 and December 1999 that were divided
into 3 diﬀerent subgroups. There were 151 patients (38%) in
the 70–74 years old group, 101 patients (27%) in the 75–79
yearsold groups, and141 patients (36%) in the >80 years old
group. Majority of our patient population was non-Hispanic
blacks in all age groups (63%, 65%, and 52%), followed
by Hispanics (26%), then white non-Hispanic (11%) and
Asians (3%). The characteristics of the patients identiﬁed
through the tumor registry are outlined in Table 1.I n f o r -
mation on whether the patients presented with a palpable
breast mass or were diagnosed based on mammography,
as well as information on the patients’ functional status
and comorbidities were not available in the tumor registry
database. There was no signiﬁcant diﬀerence in the tumor
size for all age groups (median size was 3.0cm). Only 7%
of all patients have a tumor size of <1.0cm (nonpalpable).
Thirty-nine percent of patients diagnosed were designated as
having Stage II disease. Stage IV disease accounted for 3%
of total cases. Ductal carcinoma was still the most common
histologic type demonstrated in all age groups (69%, 67%,
and 62%). Tumor grade was not identiﬁed in roughly half
(43%) of these patients. Of those with tumor grading,
moderately diﬀerentiated tumors were found to be most
predominant.Completestagingwasdonein71%ofpatients.
It was noted to be omitted more in women older than
80, but was not statistically signiﬁcant (P ≤ 0.20). About
forty-three percent of tumors expressed estrogen receptors.
However, about 46% of tumors had unknown estrogen
receptor status. Similarly, only 36% of tumors had known
positive progesterone status and was unknown in 46%.
Surgery was not performed in about 11% of the patients
(P ≤ 1). Breast conservation surgery (lumpectomy) was
performed in about 42% of all patients, while mastectomy
was done in 46% of patients. Of the patients who did not
undergo surgery, it was not indicated in the tumor registry
database as to whether they were not candidates or whether
the patients had refused the procedure. Adjuvant therapy
such as chemotherapy, radiation therapy, and hormonal
therapy were done in 12%, 25%, and 38%, respectively.
The use of chemotherapy was noted to have no signiﬁcant
diﬀerence in the three age groups. The same observation was
noted for radiation and hormonal therapy with P values of
≤0.10 and ≤1 ,r e s p e c t i v e l y .H o w e v e r ,s u r v i v a ld a t aa f t e rﬁ v e
years of diagnosis showed signiﬁcant diﬀerence between the
75–79 and ≥80 age groups (P ≤ 0.001) as well as that of the
70–74 and the ≥80 age groups (P ≤ 0.001). Overall ﬁve-year
survival was only 14% for the ≥80 age group, compared to
thatof32%and35%forthe70–74andthe75–79agegroups,
respectively. No signiﬁcant diﬀerence was noted between the
70–74andthe75–79agegroupsintermsofﬁve-yearsurvival
(P ≤ 1).
The type of therapy, if any, in addition to either mastec-
tomy or lumpectomy was likewise analyzed from the tumor
registry database and presented in Table 2. For patients who
underwent mastectomy, there was note of a trend to oﬀer
adjuvant treatment to the younger cohort (70–74 versus
≥80 years old). However, the diﬀerence was not statistically
signiﬁcant (P ≤ 0.20). Chemotherapy and radiation therapy
were given more to younger patients. That of hormonal
therapy was noted to be the same. For those patients who
underwent lumpectomy, the opposite trend was observed.
Patients who were older were given more adjuvant treatment
than the younger age group although again, the diﬀerence
did not have statistical signiﬁcance. Of note is that there
were no patients given chemotherapy in those who had
lumpectomy in the 70–74 age group, whereas about 20%
received such therapy in the 80 and older group (P ≤ 0.01).
The results in Table 3 showed that 47% of patients
found to have positive lymph nodes received some form ofInternational Journal of Breast Cancer 3
Table 1: Patient characteristics (1989–1999).
Characteristic
Age
Total P value
70–74 75–79 ≥80
Patients, number (%) 151 (38) 101 (27) 141 (36) 393 (100) NA
Race, number (%)
P ≤ 0.001
S
Black, non-Hispanic 95 (63) 66 (65) 73 (52) 234 (59)
Asian 0 (0) 5 (5) 7 (5) 12 (3)
White, non-Hispanic 39 (26) 2 (2) 2 (1) 43 (11)
Hispanic 17 (12) 28 (28) 59 (42) 104 (26)
Size of tumor, median ± standard
deviation, cm 3.0 ± 2.7 2.5 ± 2.0 3.0 ± 1.96 NA NA
Size of tumor, number (%)
NA <1cm (nonpalpable) 8 (5) 7 (7) 12 (9) 27 (7)
≥1cm (palpable) 126 (84) 82 (80) 113 (80) 321 (82)
Unknown 16 (11) 13 (13) 16 (11) 45 (11)
Stage, number (%)
P ≤ 0.20
NS
01 0 1 3 7 3 0 ( 8 )
1 38 22 33 93 (24)
2 59 39 54 152 (39)
3 23 9 24 56 (14)
4 20 16 24 60 (15)
Unknown 1 2 8 11 (3)
Histologic type, number (%)
P ≤ 1
NS
Ductal 104 (69) 68 (67) 88 (62) 260 (66)
Lobular 4 (3) 4 (4) 10 (7) 18 (4)
Papillary 2 (1) 1 (1) 1 (1) 4 (1)
Other 41 (27) 28 (28) 42 (30) 111 (28)
Grade, number (%)
P ≤ 1
NS
1( w e l ld i ﬀerentiated) 7 (5) 6 (6) 6 (4) 19 (5)
2( m o d e r a t e l yd i ﬀerentiated) 48 (32) 26 (26) 52 (37) 126 (32)
3 (poorly diﬀerentiated) 24 (16) 13 (13) 20 (14) 57 (14)
Unknown 72 (48) 55 (54) 63 (45) 190 (43)
Estrogen receptor, number (%)
P ≤ 0.20
NS
Positive 69 (46) 44 (44) 58 (41) 171 (43)
Negative 14 (9) 21 (21) 13 (9) 48 (12)
Unknown 68 (45) 48 (47) 70 (50) 186 (47)
Progesterone receptor, number (%)
P ≤ 1
NS
Positive 63 (42) 32 (32) 45 (32) 140 (36)
Negative 24 (16) 21 (21) 26 (18) 71 (18)
Unknown 64 (42) 48 (47) 70 (50) 182 (46)
Surgical Procedure, number (%)
P ≤ 1
NS
Mastectomy 66 (44) 50 (49) 65 (46) 181 (46)
Lumpectomy 67(44) 42 (41) 60 (42) 168 (42)
No surgery 18 (12) 9 (9) 16 (11) 43 (11)
Chemotherapy, number (%)
P ≤ 0.20
NS Yes 22 (14) 12 (12) 11 (8) 45 (12)
No 129 (85) 89 (88) 130 (92) 348 (88)
Radiation therapy, number (%)
P ≤ 0.10
NS Yes 47 (31) 21 (21) 30 (21) 98 (25)
No 104 (69) 80 (79) 111 (79) 295 (75)4 International Journal of Breast Cancer
Table 1: Continued.
Characteristic
Age
Total P Value
70–74 75–79 ≥80
Hormonal therapy, number (%)
P ≤ 1
NS Yes 58 (39) 38 (38) 52 (37) 148 (38)
No 93 (61) 63 (62) 89 (63) 245 (62)
Had complete staging, number (%)
P ≤ 0.20
NS Yes 115 (76) 73 (72) 93 (66) 281 (71)
No 36 (24) 28 (28) 48 (34) 112 (28)
Alive at 5 years after initial contact,
number (%) P ≤ 0.001
S Yes 49 (32) 35 (35) 20 (14) 104 (26)
No 102 (67) 66 (65) 121 (86) 289 (73)
Abbreviation: NA: not applicable; NS: not signiﬁcant; S: signiﬁcant.
Table 2: Type of surgery and adjuvant treatment (1989–1999).
Type
Age
Total P value
70–74 75–79 ≥80
Had mastectomy, number (%) 66 (44) 50 (49) 65 (46) 181 (46)
P ≤ 0.20
NS
Alone 28 (42) 29 (58) 37 (57)
With any adjuvant treatment 38 (58) 21(42) 28 (33)
With radiation therapy 9 (14) 2 (4) 2 (3)
With chemotherapy 7 (11) 4 (8) 3 (5)
With hormonal therapy 22 (33) 15 (30) 23 (35)
Had lumpectomy, number (%) 67 (44) 42 (41) 60 (42) 168 (42)
P ≤ 0.01
S
Alone 24 (36) 7 (17) 14 (23)
With any adjuvant treatment 43 (64) 35 (83) 46 (77)
With radiation therapy 22 (33) 12 (29) 15 (25)
With chemotherapy 0 (0) 3 (7) 12 (20)
With hormonal therapy 21 (31) 20 (48) 19 (32)
Abbreviation: NA: not applicable; NS: not signiﬁcant; S: signiﬁcant.
Table 3: Indications for adjuvant therapy and rates of treatment (1989–1999).
Indication
Age
Total P value
70–74 75–79 ≥80
Positive lymph nodes, number 40 25 31 96 NA
Received chemotherapy, number (%)
P ≤ 1
NS Yes 22 (55) 12 (48) 11 (35) 45 (47)
No 18 (45) 13 (52) 20 (64) 51 (53)
Positive margins of resection, number 47 27 44 113 NA
Received radiation therapy, number (%)
P ≤ 0.05
S Yes 42 (89) 21 (78) 30 (68) 98 (87)
No 5 (11) 6 (22) 14 (32) 25 (13)
Progesterone receptor positive, number (%) 63 (42) 32 (32) 45 (32) 140 NA
Estrogen receptor positive, number (%) 69 (46) 44 (43) 58 (41) 171 NA
Received hormonal therapy, number (%)
P ≤ 1
NS Yes 58 (84) 38 (86) 52 (90) 148 (86)
No 11 (16) 6 (14) 6 (10) 23 (14)
Abbreviation: NA: not applicable; NS: not signiﬁcant; S: signiﬁcant.International Journal of Breast Cancer 5
chemotherapy either with a single agent or multiple agents.
About 55% of patients in the 70–74 years age group received
chemotherapy as opposed to only 35% in those 80 years
old and greater. However, this diﬀerence was not signiﬁcant
(P<1). There were 113 patients with positive margins
of resection. Of those, 87% received radiation therapy.
However, there was a signiﬁcant diﬀerence in the number
of patients who received radiation therapy in the 70–74
compared to that in the ≥80 age group (P ≤ 0.025). In
patients with hormone receptor positive status,84% received
hormone therapy in the 70–74 age group and about 90% in
the ≥80 age group.
4. Discussion
Previous studies have suggested that age was the strongest
predictor of lesser treatment [3, 4] and that was what we
sought to validate in the study. Our data have shown that
there are observable diﬀerences in the diﬀerent parameters
measured among the subgroups and that there was a trend
for the older cohort to be undertreated compared to the
younger cohorts, but most of these observations were not
deemed statistically signiﬁcant.
An o t a b l ed i ﬀerence was that of survival after ﬁve years
of diagnosis. Signiﬁcant diﬀerences were noted between
the 80 and older age group and the 70–74 and 75–79
age groups. However, whether or not age alone in this
case is the strongest predictor for survival cannot be fully
determined. But besides age, perhaps the ﬁndings also imply
that survival is impacted by other parameters besides the
tumor and patient characteristics identiﬁed in the study and
that perhaps functional status and comorbidities play a role.
Previous studies in other cancer researches have shown that
central to the decision making in the elderly is the concept of
life expectancy [15, 16]. It is true that breast cancer increases
with age. At the same time, as the age increases, the risk of
death from causes besides breast cancer also increases [17].
Then, there is variability within an age cohort, with frail 70
year olds and robust 80 year olds. It is, therefore, signiﬁcant
to consider the patient’s functional status and comorbidities
in determining maximum treatment beneﬁts for patients. It
has been shown, for example, in cancer patients that poor
functional status correlates with worse outcomes regardless
of the type of cancer [18]. In weighing the beneﬁts and
risks of treatment therefore, breast cancer-speciﬁc prognosis,
nonbreast-cancer-speciﬁc prognosis, and treatment-related
toxicitiesshouldbeaccountedfor.TheNationalComprehen-
sive Cancer Network [19] has recommended the inclusion
of the use of a geriatric assessment tool in developing care
plans for the elderly cancer patient. Whether the assumption
therefore, that perhaps functional status and comorbidities
have contributed largely to the diﬀerence in survival cannot
be determined as information was not available in the tumor
registry.
Surgeryisstillthemainstayoftreatmentforpatientswith
early stage cancer. It has been shown that breast conservation
surgery which involves lumpectomy with or without subse-
quent axillary dissection, followed by irradiation, has equal
eﬃcacy to more extensive surgical options such as mastec-
tomy. However, current data suggests that elderly women
a r el e s sl i k e l yt ob eo ﬀered breast conservation surgery than
their younger counterparts (25% versus 42%) [20, 21]. Our
study has shown that in this institution, mastectomy and
lumpectomy were performed at almost the same frequency
although adjuvant therapy was omitted in most cases.
Staging was done for majority of patients (71%). There
was no diﬀerence between age groups (P<0.20) although
younger patients were staged more than the 80 years and
older cohort. Again, whether this was because of age alone
cannot be determined.
Still regardless of age, inﬁltrating ductal carcinoma is
the most common histologic subtype as demonstrated in
our study as well. Older patients have also been noted to
have a greater frequency of tumors with more indolent
histologiesandoverallmorefavorablebiologictumorproﬁle.
Older women are likely to express estrogen and progesterone
receptors, which improves prognosis. This also makes them
candidates for adjuvant hormonal therapy [22, 23]. In
our study, majority of the patients with positive hormone
receptor status received hormonal therapy. As suggested by
prior studies, treatments that oﬀer less toxicity are oﬀered to
patients with advanced age. Hormonal therapy which carries
less risks and toxicity compared to chemotherapy is more
likely to be oﬀered and given to elderly patients with breast
cancer.
With regard to chemotherapy, cytotoxic drugs most
commonly used in this setting like cyclophosphamide,
methotrexate, and 5-ﬂuorouracil represent the second line of
systemic therapeutic agents available for women with breast
cancer.Thereispaucityofdatawhenitcomestowomenover
the age of 70. In the Early Breast Cancer Trials Collaborative
Group, it was shown that chemotherapy did not oﬀer any
advantage in survival for women over the age of 70 [24].
However, part of the limitation of this study was that there
were very few cohorts over age 75 and that dosing was much
lesscomparedtotheyoungerpatientcohorts.Ourstudyhave
shown that chemotherapy was not generally oﬀered to our
study cohort and although there was no statistical diﬀerence,
there was note of a trend to give less chemotherapy as the
patient gets older (see Table 3) .T h i sm a ys t e mf r o mi s s u e s
of toxicity of these agents and also by suggestions of less
advantage as presented in previous trials.
Radiation therapy is well tolerated in the elderly. It
decreases ipsilateral breast cancer recurrence after breast
conservation surgery and chest wall recurrence after a
mastectomy. Our study showed that in patients 80 years
and older, radiation therapy was given less than that in the
70–74 year old cohort (see Table 1), which is reasonable
given numerous data that merely show a decrease in local
recurrence but ultimately had no eﬀect on survival [25,
26] .Ap r e v i o u ss t u d yb yF y l e se ta l .[ 27] showed that
despite reduced risk of local (7.7 to 0.6% P<0.001) and
axillary (2.5 to 0.5% P<0.49) recurrence, there was no
signiﬁcant diﬀerence in survival. The study of Ragaz et al.
[28]demonstratedthesametrendofdecreaseinlocoregional
recurrence but no advantage in decreasing distant metastasis
or improving survival. It may be reasonable, therefore, to6 International Journal of Breast Cancer
oﬀer radiation therapy to patients who may beneﬁt most
such as those with life expectancy greater than 5 years,
those with large tumors, positive lymph nodes, or negative
hormone receptors.
5. Conclusions
Treatment of breast cancer in the elderly patient in a com-
munity setting, which in this case is The Brooklyn Hospital
Center, has shown that there is a trend to having undertreat-
ment with advancing age. It was likewise demonstrated that
despite similar patient and tumor characteristics, the ﬁve-
year survival signiﬁcantly diﬀered among the diﬀerent age
cohorts. To validate whether this is due to age alone, data
on comorbidities and the patients’ functional status should
also be determined. It would also be signiﬁcant to determine
whether the patients recorded as not having received therapy
were actually oﬀered but refused, or never oﬀered because of
variousreasonsatall,asthatwoulddemonstratemoreclearly
the treatment practices as it relates to age and other patient
characteristics.
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